Gapping down
News:
- SPRY -59.1% (receives Complete Response Letter from FDA for neffy NDA)
- HLVX -12.6% (prices offering of 8.0 mln shares of common stock at $12.50 per share)
- TSHA -9.2% (discontinuing development of TSHA-120 in GAN)
- EBC -8.3% (CATC to merge with EBC)
- IONS -4.3% (treatment of hereditary angioedema granted orphan designation yesterday)
- PR -3.2% (prices secondary offering of 21.45 mln shares of common stock at $13.05 per share)
- BPTS -2.5% (provided an update yesterday on its early access programs for Sarconeos (BIO101) in the treatment of severe forms of COVID-19; exploring possibilities of launching early access programs in other key countries in Europe)
- PSO -2.3% (announces the appointment of Omar Abbosh as its new Chief Executive Officer and Executive Director effective early 2024)
- VIR -2% (announced that Johanna Friedl-Naderer the Company's Executive Vice President and Chief Operating Officer will be leaving the Company on September 29 2023)
Analyst comments:
- NCNO -4.2% (downgraded to Underweight from Equal-Weight at Morgan Stanley)
- ZBRA -3% (downgraded to Underweight from Equal-Weight at Morgan Stanley)
- CHWY -1.5% (downgraded to Perform from Outperform at Oppenheimer)